Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
Chest, doi:10.1378/chest.07-0227
doi:10.1378/chest.07-0227
(Chest. 2007; 132:135-140)
© 2007 American College of Chest Physicians
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomoda, K.
Right arrow Articles by Kimura, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomoda, K.
Right arrow Articles by Kimura, H.

Elevated Circulating Plasma Adiponectin in Underweight Patients With COPD*

Koichi Tomoda, MD, PhD; Masanori Yoshikawa, MD, PhD; Takefumi Itoh, MD, PhD; Shinji Tamaki, MD; Atsuhiko Fukuoka, MD, PhD; Kazuyuki Komeda, MD and Hiroshi Kimura, MD, PhD, FCCP

* From the Second Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.

Correspondence to: Koichi Tomoda, MD, PhD, Second Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan; e-mail: ktomoda{at}nmu-gw.naramed-u.ac.jp

Abstract

Background: Adiponectin is an adipose tissue-derived specific protein that has antiinflammatory as well as antiatherosclerotic effects. In the United States, many patients with COPD are obese and die of cardiovascular diseases. However, in Japan, patients with COPD are frequently cachexic and die of respiratory failure. This study was designed to investigate the role of adiponectin in these differences in characteristics of COPD.

Methods: We enrolled normal-weight and underweight male patients with COPD (n = 31; age, 71 ± 1 years; body mass index [BMI], 20.1 ± 0.6 kg/m2) and age-matched, healthy, male, control subjects (n = 12). The adiponectin levels were measured by enzyme-linked immunosorbent assay. Correlation of adiponectin levels with pulmonary function and serum levels of proinflammatory cytokines (tumor necrosis factor [TNF]-{alpha} and interleukin-6) were estimated.

Results: Adiponectin levels in patients with COPD were significantly higher than those in control subjects (p<0.01) and inversely correlated with BMI (r = – 0.55, p<0.01). Even in the normal-weight patients with COPD, adiponectin levels were significantly higher than those in control subjects (p<0.01). Adiponectin levels in patients with COPD significantly correlated with percentage of predicted residual volume (r = 0.40, p<0.05). In patients with TNF-{alpha} levels > 5 pg/mL, there was a significant correlation between plasma adiponectin and serum TNF-{alpha} levels (r = 0.68, p<0.05).

Conclusions: Plasma adiponectin levels in patients with COPD were elevated and correlated with body weight loss, hyperinflation, and systemic inflammation. Increased adiponectin may reduce cardiovascular events in underweight patients with COPD.

Key Words: adiponectin • cardiovascular disease • COPD • hyperinflation • underweight






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Chest Physicians.